The main aim of the European Organization for Research and Treatment of Cancer (EORTC) is to conduct, develop, coordinate and stimulate research in Europe on the experimental and clinical bases of cancer treatment in Europe. More than 2000 clinicians/researchers and 300 core medical institutions participate in the phase I, II and large, prospective, randomized, multi-center, phase III clinical trials carried out by 20 different E0RTC Cooperative Groups. The EORTC Data Center is a unique central facility in Europe that offers a comprehensive approach to cancer research and to the management of cancer clinical trials. The main objective of the EORTC Data Center is to provide logistic and scientific support to the EORTC Cooperative Groups with respect to the management of cancer clinical trials. This includes expertise in various areas such as protocol ans CRF development, regulatory requirements based on both national and international legislation, data management, computer, statistical and medical sciences as well as cancer related problems such as Quality of Life and Health Economics. It ensures from ain independent, objective, academic point of view, the highest possible quality of the trial, from its design to the final analysis and publication of the final results.
The aim of this competing continuation grant application is to request continuation of the support that the EORTC Data Center has received without interruption since 1974 so that it can pursue, reinforce and expand the range of services which it offers to the well established network of investigators participating in the activities of the EORTC Cooperative Groups.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA011488-32
Application #
6475719
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1981-12-01
Project End
2005-11-30
Budget Start
2001-12-01
Budget End
2002-11-30
Support Year
32
Fiscal Year
2002
Total Cost
$438,762
Indirect Cost
Name
European Org/Research/Treatment/Cancer
Department
Type
DUNS #
City
Brussels
State
Country
Belgium
Zip Code
1200
Tajik, Parvin; van de Vrie, Roelien; Zafarmand, Mohammad H et al. (2018) The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy. Int J Gynecol Cancer 28:453-458
Ediebah, Divine E; Reijneveld, Jaap C; Taphoorn, Martin J B et al. (2017) Impact of neurocognitive deficits on patient-proxy agreement regarding health-related quality of life in low-grade glioma patients. Qual Life Res 26:869-880
Seymour, Lesley; Bogaerts, Jan; Perrone, Andrea et al. (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143-e152
Schwartz, Lawrence H; Litière, Saskia; de Vries, Elisabeth et al. (2016) RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer 62:132-7
Baumert, Brigitta G; Hegi, Monika E; van den Bent, Martin J et al. (2016) Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17:1521-1532
Schwartz, Lawrence H; Seymour, Lesley; Litière, Saskia et al. (2016) RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur J Cancer 62:138-45
Bonnefoi, H; Jacot, W; Saghatchian, M et al. (2015) Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Ann Oncol 26:325-32
Ediebah, Divine E; Galindo-Garre, Francisca; Uitdehaag, Bernard M J et al. (2015) Joint modeling of longitudinal health-related quality of life data and survival. Qual Life Res 24:795-804
Fei, F; Messina, C; Slaets, L et al. (2015) Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trial. Eur J Cancer 51:301-9
Oosterveld, Margriet; Suciu, Stefan; Muus, Petra et al. (2015) Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studie Ann Hematol 94:23-34

Showing the most recent 10 out of 338 publications